ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1052

Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

Joanna Marco1 and Elizabeth Ferucci2, 1University of Washington, Seattle, WA, 2Alaska Native Tribal Health Consortium, Anchorage, AK

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, interstitial lung disease, pulmonary, rheumatoid arthritis, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a number of connective tissue diseases that can be associated with ILD, but no previous  studies have examined the clinical characteristics of connective tissue disease-associated ILD (CTD-ILD) in AI/AN populations. We sought to describe the spectrum of CTD-ILD in the AI/AN population in Alaska.

Methods: Through this retrospective chart review conducted at the Alaska Native Medical Center, 45 AI/AN adults with a clinical diagnosis of CTD-ILD were identified.  A detailed medical record abstraction was performed for each potential case.  Clinical characteristics are reported, including demographics, underlying CTD, ILD subtypes, serologies, pulmonary function tests (PFTs) with changes over time, and medications prescribed.

Results: Underlying connective tissue disease diagnosis was heterogeneous in this population. Rheumatoid arthritis (RA) was the most common (n = 13), followed by systemic sclerosis (SSc, n = 12; limited cutaneous n = 7, diffuse cutaneous n = 5), and mixed connective tissue disease (MCTD, n = 9). The mean age at connective tissue disease diagnosis was 45 (standard deviation (SD) 15), and the mean age at ILD diagnosis was 52 (SD 14), for a mean time from CTD diagnosis to ILD diagnosis of 7 years. Most patients were diagnosed with usual interstitial pneumonia (UIP) by high resolution CT (HRCT) (60%). The baseline forced vital capacity (FVC) was 68 percent predicted, and fell by an average of 1.2 absolute percentage points per year. The baseline diffusing capacity of the lungs for carbon monoxide (DLCO) was 56 percent predicted and fell by an average of 5.1 absolute percentage points per year.

Conclusion: This study is the first to describe patterns of CTD-ILD in any AI/AN population. As in other populations, RA-ILD and SSc-ILD are common, but this population additionally had a high proportion of ILD associated with of MCTD. Understanding the clinical characteristics of CTD-ILD in this population may improve recognition and care of CTD-ILD in AI/AN people.


Disclosure: J. Marco, None; E. Ferucci, None.

To cite this abstract in AMA style:

Marco J, Ferucci E. Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/connective-tissue-disease-related-interstitial-lung-disease-in-american-indian-alaska-native-people-in-alaska/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/connective-tissue-disease-related-interstitial-lung-disease-in-american-indian-alaska-native-people-in-alaska/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology